|Artificial Intelligence Revolutionizing the Pharmaceutical Industry|
|Optimal Synergy Between Leading-edge Computational Science and Therapeutics Development|
The impressive advances in life sciences research and development (R&D) befallen in the past two-three years are playing a leading role in the transformation of the healthcare industry. A myriad of new developments in the fields of gene and cell therapies, empowered with nanotechnology advances, omics technologies and novel smart molecules approaches, are extensively enlighten drug discovery and development landscape for the effective treatment of diseases. AI is pursued to provide the best suited approach to leverage scientific literature, patient’s omics-data and overall clinical data, to drive smart decisions.
Research Scope: Unveiling AI-driven Technology
Beyond paving the way for medical research toward precision medicine through a stratified therapeutics discovery and development approach, AI-driven technology companies are demonstrating an outstanding ability to exploit scientific results and AI learning systems synergy to guarantee successful clinical translation of therapeutic, diagnostic, and theranostic developments.
Frost & Sullivan investigated the AI-based precision medicine industry by leveraging its robust in-house database, enriched with primary interviews with providers, developers, and users of AI-based medical solutions to identify and evaluate key opportunities, applications, and needs.
The study illustrates the following: